NanoViricides (NYSE-A:NNVC) CEO Anil Diwan joined Steve Darling from Proactive to share news about the company that is using its nanoviricide platform technology to develop drugs that fight against viruses.
Diwan tells Proactive some of the drugs in development include its most advanced which deals with Shingles. The company is also looking at cold sores, influenza, genital lesions, rabies and Ebola.
Diwan also shared with Proactive the company has signed a licensing agreement with Karveer Meditech in India for the right to commercialize the company's COVID drugs NV-CoV-2 and NV-CoV-2-R.